Clinical Trial Update: Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Peripheral Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AZD1386 for peripheral neuropathic pain has been terminated. The sponsor is AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Neuropathic Pain

Drugs mentioned

• AZD1386 (Capsaicin)

Snippet

Sponsor: AstraZeneca | Conditions: Pain, Neuropathic Pain | Phase 2 | Status: TERMINATED